Plan Development for Giving Teclistamab in the Outpatient Setting

Abroad (travel likely)RecruitingPHASE4

Conditions

Multiple Myeloma · Relapsed Cancer · Refractory Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Study leads

Christine Chen, Dr.
Principal Investigator
University Health Network, Toronto

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Relapsed · Refractory · Multiple Myeloma

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Denver, United States

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Multiple Myeloma · Refractory B-Cell Non-Hodgkin Lymphoma

Abroad (travel likely)Recruiting

Columbus, United States

A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)

Abroad (travel likely)Recruiting

Milan, Italy · Bari, Italy